CPB Budapest 2017

IGR phase III trial

• No significant differences in local control and survival

• Overall complications and side effects

observed after 6 months significantly more frequent ( p < 0.01) in the higher dose rate group

Haie e.a. Int. J. Radiat. Oncol. Biol. Phys. 29, 953-960, 1994 .